A new trading day began on Tuesday, with Xeris Biopharma Holdings Inc (NASDAQ: XERS) stock price up 1.56% from the previous day of trading, before settling in for the closing price of $4.48. XERS’s price has ranged from $2.03 to $6.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 136.89% over the past five years. Meanwhile, its annual earnings per share averaged 77.03%. With a float of $147.60 million, this company’s outstanding shares have now reached $156.01 million.
Let’s look at the performance matrix of the company that is accounted for 394 employees. In terms of profitability, gross margin is 80.99%, operating margin of -10.11%, and the pretax margin is -21.41%.
Xeris Biopharma Holdings Inc (XERS) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Xeris Biopharma Holdings Inc is 7.84%, while institutional ownership is 54.43%. The most recent insider transaction that took place on May 09 ’25, was worth 277,668. Before that another transaction happened on Mar 20 ’25, when Company’s insider sold 40,000 for $5.43, making the entire transaction worth $217,244. This insider now owns 1,353,510 shares in total.
Xeris Biopharma Holdings Inc (XERS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 77.03% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Here are Xeris Biopharma Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.30, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.10 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Xeris Biopharma Holdings Inc (NASDAQ: XERS) saw its 5-day average volume 2.31 million, a negative change from its year-to-date volume of 2.58 million. As of the previous 9 days, the stock’s Stochastic %D was 28.96%. Additionally, its Average True Range was 0.25.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 48.03%, which indicates a significant increase from 30.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.31% in the past 14 days, which was lower than the 62.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.61, while its 200-day Moving Average is $3.74.
